111 related articles for article (PubMed ID: 10784392)
1. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Cortes J; Estey E; Beran M; O'Brien S; Giles F; Koller C; Keating M; Kantarjian H
Leuk Lymphoma; 2000 Feb; 36(5-6):479-84. PubMed ID: 10784392
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].
Qin TJ; Xu ZF; Wang JY; Zhou CL; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1342-6. PubMed ID: 19840480
[TBL] [Abstract][Full Text] [Related]
3. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Vey N; Kantarjian H; Beran M; O'Brien S; Cortes J; Koller C; Estey E
Invest New Drugs; 1999; 17(1):89-95. PubMed ID: 10555127
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
[TBL] [Abstract][Full Text] [Related]
6. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
[TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Kantarjian HM; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios MB; Plunkett W; Keating MJ
Blood; 1993 Mar; 81(5):1146-51. PubMed ID: 8382970
[TBL] [Abstract][Full Text] [Related]
9. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cortes J; Tsimberidou AM; Alvarez R; Thomas D; Beran M; Kantarjian H; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2002 Dec; 50(6):497-500. PubMed ID: 12451477
[TBL] [Abstract][Full Text] [Related]
10. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Giles FJ; Cortes JE; Kantarjian HM; O'Brien SM; Estey E; Beran M
Leuk Res; 2004 Apr; 28(4):353-7. PubMed ID: 15109534
[TBL] [Abstract][Full Text] [Related]
11. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien S; Cortes J; Koller CA; Giles FJ; Kornblau S; Andreeff M; Vey N; Pierce SR; Hayes K; Wong GC; Keating M; Kantarjian H
J Clin Oncol; 1999 Sep; 17(9):2819-30. PubMed ID: 10561358
[TBL] [Abstract][Full Text] [Related]
12. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
Kornblau SM; Kantarjian H; O'Brien S; Andreeff M; Koller CA; Beran M; Keating M; Estey E
Leuk Lymphoma; 1998 Jan; 28(3-4):371-5. PubMed ID: 9517508
[TBL] [Abstract][Full Text] [Related]
13. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
[TBL] [Abstract][Full Text] [Related]
14. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
15. High-dose ara-C and etoposide in refractory or relapsing acute leukemia.
Freund M; Link H; Diedrich H; LeBlanc S; Wilke HJ; Poliwoda H
Cancer Chemother Pharmacol; 1991; 28(6):487-90. PubMed ID: 1934254
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL
Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Suki S; Kantarjian H; Gandhi V; Estey E; O'Brien S; Beran M; Rios MB; Plunkett W; Keating M
Cancer; 1993 Oct; 72(7):2155-60. PubMed ID: 8374873
[TBL] [Abstract][Full Text] [Related]
18. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
19. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Beran M; Kantarjian H; O'Brien S; Koller C; al-Bitar M; Arbuck S; Pierce S; Moore M; Abbruzzese JL; Andreeff M; Keating M; Estey E
Blood; 1996 Oct; 88(7):2473-9. PubMed ID: 8839838
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Crump M; Lipton J; Hedley D; Sutton D; Shepherd F; Minden M; Stewart K; Beare S; Eisenhauer E
Leukemia; 1999 Mar; 13(3):343-7. PubMed ID: 10086724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
